A novel bedside rule-in test for tuberculous meningitis in human immunodeficiency virus-infected adults
(See the Major Article by Quinn et al on pages e3428-34.)Tuberculous meningitis (TBM) likely affects >100 000 people per year [1]. While this represents approximately 1% of all tuberculosis (TB) cases, TBM is disproportionately important because it kills or severely disables half of those affecte...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
6 January 2021
|
| In: |
Clinical infectious diseases
Year: 2021, Volume: 73, Issue: 9, Pages: e3435-e3437 |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/ciaa1915 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/cid/ciaa1915
|
| Author Notes: | Tobias Broger and Mark P. Nicol |
| Summary: | (See the Major Article by Quinn et al on pages e3428-34.)Tuberculous meningitis (TBM) likely affects >100 000 people per year [1]. While this represents approximately 1% of all tuberculosis (TB) cases, TBM is disproportionately important because it kills or severely disables half of those affected [2]. Major risk factors for TBM are young age [3] and human immunodeficiency virus (HIV) infection.Diagnosis of TBM is a challenge because clinical features are nonspecific, laboratory tests are insensitive, and mycobacterial culture is too slow to have meaningful clinical impact. Treatment delay is the strongest risk factor for death [2]; sensitive diagnostics with short turnaround times are urgently needed. Rapid nucleic acid amplification tests, such as Xpert MTB/RIF Ultra (Ultra), have shown good sensitivity (77%) against culture-confirmed TBM [4], but require large cerebrospinal fluid (CSF) volumes [5] and are not yet widely available, particularly close to the point of care in many high-burden countries [6]. |
|---|---|
| Item Description: | Gesehen am 22.03.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1537-6591 |
| DOI: | 10.1093/cid/ciaa1915 |